Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-CVOT: tirzepatide versus dulaglutide for major cardiovascular events in type 2 diabetes
MOH_2020-03-31_008814Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Tirzepatide with Dulaglutide (2 arms). Primary endpoints: Time to first major adverse cardiovascular event (MACE-3) and Non-inferiority of tirzepatide versus dulaglutide for MACE-3. Started Mar 2020; status: active, not recruiting.
02
Drugs
tirzepatidedulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2020-03-31_008814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-31_008814.